Sunday, August 12, 2018 4:58:36 PM
Yes, percentages for hyper-progressive disease do vary. Hence my conservative figure of 10%.
But it is hugely under-reported.
Thousands of patients have died prematurely in hundreds of ICI clinical trials. How is it that not a single ICI clinical trial, up until about a year ago, reported any occurrences of hyperprogression?
That 10% incidence rate would have been just the same in clinical trials, as is now being shown in targeted studies.
But investigators chose to remain blinkered, and just marked it down as non-response to the investigational drug, and ordinary disease progression.
Big Pharma and the the FDA are responsible for these thousands of deaths.
And now thousands are dying in regular clinical practice.
The largest study to date on hyperprogression and NSCLC found an incidence of HPD of 16%, and an ORR of 15%....
So you know what that means..
Yes, more likely to kill you than help you.
Other studies have found a much higher incidence of HPD than 10%.
And an arm of a recent clinical trial reported 100% (6 out of 6) subjects experiencing HPD.
But it is hugely under-reported.
Thousands of patients have died prematurely in hundreds of ICI clinical trials. How is it that not a single ICI clinical trial, up until about a year ago, reported any occurrences of hyperprogression?
That 10% incidence rate would have been just the same in clinical trials, as is now being shown in targeted studies.
But investigators chose to remain blinkered, and just marked it down as non-response to the investigational drug, and ordinary disease progression.
Big Pharma and the the FDA are responsible for these thousands of deaths.
And now thousands are dying in regular clinical practice.
The largest study to date on hyperprogression and NSCLC found an incidence of HPD of 16%, and an ORR of 15%....
So you know what that means..
Yes, more likely to kill you than help you.
Other studies have found a much higher incidence of HPD than 10%.
And an arm of a recent clinical trial reported 100% (6 out of 6) subjects experiencing HPD.
Recent NWBO News
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
